FGL2 and central nervous system cancer: We have shown through a series of studies of preclinical glioma that FGL2 increases the expression of PD-1 and the frequency of tumor-supportive macrophages and Tregs, suppresses the development of CD103+ DCs, and blocks the recruitment of tumor-specific, brain-resident memory T cells (7, 12, 13).